🔮 Better than the Oracle? Our Fair Value found this +42% bagger 5 months before Buffett bought itRead More

Tesla, Amazon, Micron, Sintx, Zymeworks: Why These 5 Stocks Are Drawing Investors' Attention Today

Published 22/12/2022, 00:47
© Reuters.  Tesla, Amazon, Micron, Sintx, Zymeworks: Why These 5 Stocks Are Drawing Investors' Attention Today
AMZN
-
MU
-
TSLA
-
IXIC
-
ZYME
-

Benzinga - U.S. markets soared on Wednesday as consumer confidence surged to an eight-month high in December following a drop in inflation and the labor market remaining strong. Twelve-month inflation expectations fell to their lowest level since Sept. 2021, at 6.7%, according to Reuters. At the same time, upbeat earnings from Nike Inc (NYSE: NYSE:NKE) and FedEx Corporation (NYSE: NYSE:FDX) also boosted market sentiments. Meanwhile, here are five stocks drawing investors’ attention:

1. Tesla Inc (NASDAQ: NASDAQ:TSLA): Tesla shares closed 0.17% lower on Wednesday but gained 0.64% in extended trading. The company told its employees it was freezing hiring for now and would implement more job cuts in the first quarter, according to a report by Electrek.

Also Read: How To Invest In Startups

2. Amazon.com (NASDAQ:AMZN), Inc. (NASDAQ: AMZN): Amazon shares closed 1.85% higher on Wednesday. Large warehouse operators including Amazon in New York State are looking at new limits on the quota systems they can use to spur worker productivity, under legislation signed into law by Gov. Kathy Hochul, reported Bloomberg Law.

3. Micron Technology Inc (NASDAQ: NASDAQ:MU): Shares of Micron closed 1.01% higher on Wednesday but lost 2.17% in extended trading. The company posted first-quarter revenue of $4.09 billion, which missed average analyst estimates of $4.12 billion.

4. SINTX Technologies Inc (NASDAQ: SINT): Shares of SINTX closed 57.16% higher on Wednesday. The company announced it received a Phase I contract for $150,000 from the U.S. Missile Defense Agency.

5. Zymeworks Inc (NASDAQ: ZYME): Shares of Zymeworks closed 23.59% higher on Wednesday. The company announced that Jazz Pharmaceuticals plc (NASDAQ: JAZZ) exercised its option to continue with its exclusive development and commercialization rights to Zymeworks' zanidatamab in key markets.

Read Next: As Tesla's Stock Falls To New 2-Year Lows, How Are Its EV Peers Performing?

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.